A call for health advocacy groups to disclose more about the pharma money they take

Posted By

Tags

A study in the American Journal of Public Health looks at drug industry contributions to non-profit health advocacy groups. The authors report:

“We used Eli Lilly and Company’s grant registry to examine its grant-giving policies. We also examined (health advocacy organization) Web sites to determine their grant disclosure patterns. Only 25% of (health advocacy organizations) that received Lilly grants acknowledged Lilly’s contributions on their Web sites, and only 10% acknowledged Lilly as a grant event sponsor. No (health advocacy organization) disclosed the exact amount of a Lilly grant. As highly trusted organizations, (health advocacy organizations) should disclose all corporate grants, including the purpose and the amount. Absent this disclosure, legislators, regulators, and the public cannot evaluate possible conflicts of interest or biases in HAO advocacy.”

ProPublica, which has been doing a lot of reporting on conflicts of interest in health care, posted the study and its story on the study.

You might also like

Comments

Please note, comments are no longer published through this website. All previously made comments are still archived and available for viewing through select posts.

Comments are closed.